

1 **The Use of Viscoelastic Haemostatic Assays in the management of major bleeding.**

2 **A British Society for Haematology Guideline**

3 Curry N.,^{1,2} Davenport R.,³ Pavord S.,^{1,2} Mallett S.V.,⁴ Kitchen D.,⁵ Klein A.A.,⁶ Maybury

4 H.,⁷Collins P.W.,⁸ Laffan M.⁹

5 Authors' affiliations

6 1 – Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU.

7 2 – NIHR BRC, Blood Theme, Oxford University, OX3 9DU.

8 3 - Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, E1 2AT.

9 4 - Department of Anaesthesia, Royal Free London NHS Foundation Trust, London, NW3 2QG.

10 5 – UK NEQAS for Blood Coagulation, Sheffield, S10 2QD.

11 6 – Department of Anaesthesia and Intensive Care, Royal Papworth Hospital, Cambridge, CB23 3RE.

12 7 – Department of Obstetrics, Leicester Royal Infirmary, Leicester, LE5 4PW.

13 8 – Department of Haematology, School of Medicine, Cardiff University, Cardiff, CF14 4XN.

14 9 – Department of Haematology, Imperial College and Hammersmith Hospital, London, W12 0HS.

15

16

17 Correspondence:

18 BSH Administrator, British Society for Haematology, 100 White Lion Street, London, N1 9PF,

19 UK. E-mail: bshguidelines@b-s-h.org.uk

20

21 Running Title:

22 Viscoelastic tests in the management of major bleeding.

23

24 Key words:

25 TEG, ROTEM, Sonoclot, major bleeding, viscoelastic tests

26

27

28

29

1 Major haemorrhage is an important cause of morbidity and mortality, affecting up to 40% of
2 all trauma patients (Stanworth *et al*, 2016) and 10% of cardiac surgery patients (Serraino &
3 Murphy, 2017). Blood loss is one of the main causes of morbidity following liver
4 transplantation (Gurusamy *et al*, 2011) and is one of the most common causes of death
5 worldwide in women at the time of delivery (Say *et al*, 2014). Diagnosis of major bleeding is
6 difficult and is often made using clinical measures (e.g. rising heart rate, falling blood
7 pressure) but these measures can be insensitive, particularly in younger patients in whom
8 blood loss can be masked and haemodynamic stability preserved or in elderly patients on
9 cardiovascular modulating medication. Detection and correction of coagulopathy is
10 therefore an important aspect of management of severe haemorrhage.

11

12 BSH guidelines (Hunt *et al*, 2015) recommend the use of serial standard laboratory tests
13 (SLTs) taken every 30-60 minutes to monitor major haemorrhage in most clinical settings.

14 There are, however, inherent difficulties with SLTs. Average turn-around-times are between
15 27 (Cotton *et al*, 2011) and 77 minutes (Davenport *et al*, 2011) which is often too slow for a
16 rapidly evolving situation. Furthermore, the ability of SLTs to predict major bleeding and
17 therefore allow pre-emptive treatment is limited (Segal *et al*, 2005, Davenport *et al*, 2011).

18 In liver transplantation for example, it is well known that the prothrombin time (PT) or the
19 International Normalised Ratio (INR) does not differentiate between patients who will or
20 will not bleed excessively (Massicotte *et al*, 2014), nor does an elevated INR exclude
21 underlying hypercoagulability (Krzanicki *et al*, 2013).

22

23 Viscoelastic haemostatic assays (VHA) are increasingly being used during the management
24 of major bleeding. There are several recent comprehensive systematic reviews evaluating

1 the available evidence (Whiting *et al*, 2015, Serraino & Murphy, 2017, Fahrendorff *et al*,
2 2017). Current NICE guidance recommends VHA use during cardiac surgery, but not for
3 obstetric or trauma haemorrhage (Whiting *et al*, 2015). This BSH guideline recognises the
4 limited available evidence but, within these constraints, aims to provide pragmatic and
5 practical advice to practising clinicians as to how to interpret and use VHA results during the
6 management of major bleeding in four common scenarios: obstetric haemorrhage, liver
7 disease, cardiac surgery and trauma haemorrhage.

8

9 **Methodology**

10 This guideline was compiled according to the BSH process at www.b-s-h.org.uk/guidelines.
11 Details of the methodology for inclusion of studies, including the PRISMA diagram, can be
12 found in the online supplement. Grading of Recommendations Assessment, Development
13 and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess
14 the strength of recommendations. The GRADE criteria can be found at
15 <http://www.gradeworkinggroup.org>.

16

17 ***Review of the manuscript***

18 Review of the manuscript was performed by the British Society for Haematology (BSH)
19 Guidelines Committee Haemostasis and Thrombosis Task Force, the BSH Guidelines
20 Committee and the Haemostasis and Thrombosis sounding board of the BSH. It was also on
21 the members section of the BSH website for comment. The AAGBI endorsed the document.

22

23 **Machine methodology, quality assurance and test accuracy**

1 Viscoelastic tests include thromboelastography (TEG), thromboelastometry (ROTEM) and
2 Sonoclot. The most widely used machines are: TEG5000 (Haemonetics Corporation, IL, USA),
3 ROTEM delta (TEM International, GmbH) and Sonoclot (Sienco Inc, Arvada, CO, USA). Until
4 recently, all three devices used similar principles based on a cup and pin method to measure
5 the mechanical properties of clot formation in whole blood (see figures 1a, 1b, 1c). A variety
6 of activators are used for each device to examine different aspects of the haemostatic
7 system (see tables 1a, 1b, 1c) and as the blood clots a graphical representation is made. A
8 typical trace for TEG and ROTEM is shown in figure 2 and a Sonoclot trace in figure 3.
9 Although TEG and ROTEM traces look identical, the parameters are not directly
10 interchangeable and should not be regarded as equivalent (Coakley *et al*, 2006, Venema *et*
11 *al*, 2010, Rizoli *et al*, 2016, Hagemo *et al*, 2015).

12

13 One of the major drawbacks of VHA machines has been the need for users to be trained in
14 basic pipetting: the TEG5000 and Sonoclot operate with manual pipetting, the ROTEM delta
15 with automated pipetting. In response to this challenge, the TEG and ROTEM manufacturers
16 have developed cartridge based techniques designed to improve ease of use and precision –
17 the TEG6s and the ROTEM sigma.

18

19 TEG6s has microfluidic cartridges pre-loaded with reagents and uniquely uses resonance
20 technology to record clot formation (figure 4). Each cartridge has four channels, containing
21 different reagents (table 1a). Despite a different methodology, observational data have
22 shown good correlation between TEG5000 and TEG6s (R time, K time, alpha angle) (Gurbel
23 *et al*, 2016) in 157 healthy volunteers and 300 cardiac patients. But similarly to all VHA
24 devices, the TEG6s remains sensitive to vibration (Gill, 2017), an important consideration for

1 road- or air-based analysis. TEG6s cartridges to detect anti-thrombin and anti-Xa agents are
2 in development and a pilot study (Bliden *et al*, 2017) showed high sensitivity and specificity
3 for direct oral anticoagulant (DOAC) therapies.

4
5 Only one study has compared ROTEM sigma and delta: evaluating EXTEM and FIBTEM in 30
6 pregnant volunteers. This study showed no differences between FIBTEM A5 values but
7 reported significantly lower EXTEM A5 and shorter EXTEM CT values with the sigma
8 (Crichton *et al*, 2017). Further comparative data are needed exploring new versus older
9 technologies, since switching devices may require significant adjustments to the
10 corresponding VHA-based transfusion algorithm.

11

12 **Sample type and pre-analytical issues**

13 Native whole blood samples need immediate analysis. Anticoagulated samples should be
14 analysed within four hours of venesection. No specific rest period is recommended by
15 manufacturers prior to analysing citrated blood samples. Users of ROTEM devices have
16 variously recommended resting samples between 30 (Andreasen *et al*, 2011, Armstrong *et*
17 *al*, 2011) and 120 (Theusinger *et al*, 2010) minutes, whilst others report immediate testing
18 (Ogawa *et al*, 2012a, 2012b, Oswald *et al*, 2010).

19 Pragmatically, it is reasonable to perform immediate testing for all VHA tests.

20

21 **Precision and accuracy of testing**

22 Precision of VHA testing has not been widely reported, although operator variation seems to
23 have an important effect. CVs of 2.6 - 11.2% for ROTEM delta and 7.4 - 19% for TEG5000
24 parameters were reported in one study with seven operators (Anderson *et al*, 2014). Inter-

1 laboratory comparison with external quality assurance (EQA) samples shows much poorer
2 precision: 7 - 49% for TEG5000 and 7 - 83% for ROTEM delta (Kitchen *et al*, 2010). Notably
3 this EQA programme used lyophilised citrated plasma samples, which may explain the wide
4 variability. There are no EQA data for the TEG6s or ROTEM sigma.

5

6 **Internal quality control**

7 There is no consensus on the desirable frequency of Internal Quality Control (IQC) – reports
8 have ranged from eight hourly (Pommering *et al*, 2014) to weekly (Jeger *et al*, 2012). As with
9 all IQC, this methodology checks the quality control of the user, and the reagents as well as
10 the device. TEG manufacturers recommend daily electronic checks and monthly IQC for low
11 volume users and more frequent analysis for higher users. ROTEM recommends weekly
12 quality control checks and Sonoclot recommends a viscosity check daily and a monthly
13 reference plasma quality control. These are minimum recommendations and users should
14 take into account volume of testing when deciding on frequency of IQC.

15

16 **External quality assurance**

17 The UK National External Quality Assurance Scheme (NEQAS) for Blood Coagulation
18 programme provides a VHA EQA service for TEG5000 and ROTEM delta which uses
19 lyophilized citrated plasma samples with plans in place to offer EQA for TEG6s and ROTEM
20 sigma. The External quality Control of diagnostic Assays and Tests (ECAT) Foundation also
21 offers an EQA scheme using lyophilised plasma.

22

23 **Reference Ranges**

1 VHA tests are poorly standardised and apart from manufacturers' reported reference
2 ranges, there is no published consensus for normal ranges. Hospitals should therefore
3 determine local reference ranges as is standard practice for the majority of laboratory
4 tests. Determining local ranges may not be practical in the paediatric setting – reference
5 ranges have been reported for children using the ROTEM delta (Oswald et al, 2010) and the
6 TEG5000 (Chan et al, 2007).

7

8 **Practice points:**

- 9 • **Reference ranges should be determined locally and re-established when a new**
10 **machine is introduced.**
- 11 • **For non cartridge-based methods, staff should be trained and have good pipetting**
12 **technique. Training and competency should be documented.**
- 13 • **Anticoagulated samples should be tested within four hours; no resting period is**
14 **required.**
- 15 • **IQC should be performed daily for high volume usage or weekly if low volume usage.**
- 16 • **TEG and ROTEM measures must not be used interchangeably.**
- 17 • **Participation in an accredited EQA programme is recommended.**

18

19 **VHA traces**

20 Standard TEG/ROTEM traces can be divided into four main sections:

- 21 1) *Clot initiation (R (reaction) time - TEG5000; ACT (activated clotting time) – rapid TEG*
22 *or rTEG; CT (clotting time) – ROTEM devices):* is broadly similar to the PT or activated
23 partial thromboplastin time (aPTT) and measures from test start until fibrin begins to

1 be formed. Warfarin and heparin prolong this measurement, as can any other
2 significant hypocoagulability, including low fibrinogen concentration.

3 2) *Fibrin polymerisation (K (kinetics) time, α angle – TEG devices; CFT (clot formation*
4 *time), α angle – ROTEM devices):* reflects the speed at which fibrin is formed and
5 how well it binds to platelets. The value is dependent on sufficient fibrinogen and
6 platelet number and function.

7 3) *Clot strength (MA (maximum amplitude) – TEG devices; A (amplitude) and MCF*
8 *(maximal clot firmness) – ROTEM devices):* these measures make up most of the
9 trace and are a combined assessment of fibrinogen and platelet interaction. To
10 differentiate their effects the standard VHA trace should be compared with a
11 fibrinogen trace (ROTEM - FIBTEM; TEG – functional fibrinogen (ff)) in which the
12 contribution of platelets is removed by adding a platelet inhibitor. Factor XIII also
13 contributes to a small degree to clot strength.

14 4) *Lysis of the clot (LY30 (lysis at 30 minutes) – TEG devices; ML (maximal lysis) –*
15 *ROTEM devices):* some clot strength diminution is expected by the end of a VHA
16 trace, as platelet retraction is a normal phenomenon. Cut-offs are given, specific to
17 each device, and if exceeded fibrinolysis is evident. Although TEG and ROTEM are
18 able to detect increased lysis, they are insensitive to mildly and or moderately
19 increased fibrinolysis and should not be used to confirm its absence (Raza *et al,*
20 2013) nor should it be used as a reason to withhold tranexamic acid.

21 VHA tests are generally insensitive to anti-platelet agents (except $\alpha 2b\beta 3$ blockers) (Tynngård
22 *et al,* 2015). Standard ROTEM tests (EXTEM/INTEM CT) can detect DOACs (dabigatran,
23 edoxaban, rivaroxaban) at therapeutic levels, but appear insensitive to apixaban (Seyve *et*
24 *al,* 2018). Sonoclot measures are set out in figure 3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Obstetric and postpartum bleeding

VHA are most useful in major obstetric bleeding when the obstetric haemorrhage protocol is activated, though tests may be run earlier if coagulopathy is expected, e.g., with placental abruption or amniotic fluid embolism.

The coagulation system at term is procoagulant and normal ranges for many TEG and ROTEM parameters differ at delivery from non-pregnant values. On the ROTEM delta, CTs are shorter and EXTEM and FIBTEM A5 (amplitude at 5 minutes), A10 and MCF are higher for women in the third trimester of pregnancy (Armstrong *et al*, 2011; van Rheenen-Flach *et al*, 2013; de Lange *et al*, 2014; Oudghiri *et al*, 2011). On the TEG5000, R and K times are shorter and alpha angle and MA higher at term (Della Rocca *et al*, 2012; Polak *et al*, 2011). This means that an MA or MCF which is normal for the non-pregnant population may suggest a developing coagulopathy in a term woman. An abnormal ROTEM or TEG trace may help to alert clinicians to the possibility of an amniotic fluid embolus or placental abruption. There are no published data on the normal range for Sonoclot during pregnancy.

Prediction of bleeding/coagulopathy

FIBTEM and EXTEM measured on admission to delivery suite or before bleeding starts are not predictive of future bleeding (Kaufner *et al*, 2016). However, a low FIBTEM A5 and MCF, taken at the time of moderate postpartum haemorrhage (1000 to 1500 ml), is predictive of the need for transfusion of ≥ 4 units red blood cell (RBC) [Receiver operator characteristic area under the curve (ROC AUC) (95% confidence intervals (CI)) 0.78 (0.69-0.88)] and bleeds >2500 ml [0.75 (0.66-0.85)]. Women who progressed to ≥ 4 units RBC had a FIBTEM A5 of 13

1 mm (interquartile range (IQR): 10-17) whereas those that did not progress had a FIBTEM A5
2 of 19 mm (17-23) (Collins *et al*, 2014). TEG clot strength measures, using an MA cut off of 40
3 mm (kaolin TEG5000 MA) are also predictive of major obstetric haemorrhage: ROC AUC
4 (95% CI) 0.9 (0.83-0.95) (Barinov *et al*, 2016). There are no published data on the role of
5 Sonoclot for predicting progression of obstetric bleeding.

6

7 **Diagnosis of bleeding/coagulopathy**

8 Clauss fibrinogen and FIBTEM A5/MCF correlate moderately well during postpartum
9 haemorrhage (PPH) and can be used to identify women with a reduced Clauss fibrinogen
10 (Huissoud *et al*, 2009). A double blind, randomised, placebo-controlled trial of women
11 experiencing moderate to severe PPH, showed that a FIBTEM A5 >12 mm indicates a
12 fibrinogen level adequate for haemostasis (Collins *et al*, 2017a). An observational study
13 showed that the combination of an EXTEM CT <100 sec and FIBTEM A5 >12 mm was
14 associated with adequate haemostasis (Mallaiah *et al*, 2015a, 2015b).

15

16 Tranexamic acid improves outcomes during PPH if infused within 3 hours of delivery
17 (WOMAN trial, 2017). There are no data to support the use of APTEM or TEG clot lysis
18 parameters to guide tranexamic acid infusion. Normal APTEM or TEG clot lysis results should
19 not be used to withhold tranexamic acid.

20

21 There are no published data to link platelet number with ROTEM or TEG parameters during
22 PPH. Algorithms developed for other causes of bleeding may not be applicable in this
23 situation because clot strength parameters are raised at the time of delivery.

24

1 **Use of ROTEM/TEG/Sonoclot for guiding transfusion and haemostatic therapy**

2 NICE guidance does not support the use of VHAs to guide blood component replacement
3 during PPH and recommends further studies (Whiting *et al*, 2015).

4

5 A prospective, double-blind study randomised women with moderate to severe PPH and a
6 FIBTEM A5 ≤ 15 mm to fibrinogen concentrate or placebo (n=55). No reduction in
7 transfusion requirements or blood loss was reported. Subgroup analysis suggested that if
8 FIBTEM A5 ≥ 12 mm fibrinogen infusion was not required (Collins *et al*, 2017a). In the
9 observation arm of the same study, 605 women were not infused fresh frozen plasma (FFP)
10 if FIBTEM A5 was >15 mm or bleeding had stopped. This did not result in any women
11 developing clinically significant haemostatic impairment defined as continuing bleeding
12 associated with a PT or aPTT >1.5 times normal (Mavrides *et al*, 2016; Collins *et al*, 2017a;
13 2017b).

14

15 An observational study showed that infusing fibrinogen concentrate when FIBTEM A5 was
16 <7 mm, or <12 mm with severe bleeding and infusing FFP when CT was >100 s (n=107),
17 reduced RBC usage, transfusion-associated fluid overload and admission to the intensive
18 care unit (ICU) compared to the use of empirical transfusion with RBC:FFP:platelets in a ratio
19 of 4:4:1 (n=42) in a before and after study (Mallaiah *et al*, 2015a, 2015b).

20

21 An observational study compared standard care (n=29) with early surgical intervention,
22 mechanical uterine pressure plus TEG-guided transfusion (n=90). There was a statistically
23 significant reduction in hysterectomy, total blood loss and FFP transfusion in the combined
24 strategy group. The report does not state what TEG parameters were used to trigger FFP or

1 platelet transfusion. It not possible to conclude which of the interventions contributed to
2 the improved outcomes (Barinov *et al*, 2016). A TEG-based algorithm for managing
3 obstetric bleeding has been published but no data were presented on whether the
4 algorithm affected outcomes (Hill *et al*, 2012).

5

6 There are no published data on the role of Sonoclot to guide blood component use during
7 PPH.

8

9 **Recommendations**

- 10 • **VHA are not usually helpful for predicting post-partum haemorrhage when taken**
11 **during labour in a non-bleeding pregnant woman. Grade 2C.**
- 12 • **VHA may be used as part of an agreed algorithm to manage postpartum**
13 **haemorrhage when the local institution's major obstetric haemorrhage protocol is**
14 **activated. Grade 2C.**
- 15 • **During ongoing major postpartum haemorrhage, if the FIBTEM A5 is >12 mm**
16 **fibrinogen replacement is unlikely to improve clinical haemostasis. Grade 2B.**
- 17 • **During major postpartum haemorrhage, if FIBTEM A5 is <7 mm, or <12 mm with**
18 **ongoing bleeding, fibrinogen replacement may improve clinical haemostasis. Grade**
19 **2C.**
- 20 • **In a bleeding pregnant or post-partum patient tranexamic acid should not be**
21 **withheld based on the TEG or ROTEM parameters. Grade 1B.**

22

23 **Liver disease and Liver Surgery**

24 **Prediction of bleeding/coagulopathy**

1 In liver disease, VHA have a better predictive value for bleeding (Fayed *et al*, 2015, Tafur *et*
2 *al*, 2016, Pustavoitau *et al*, 2017) and re-bleeding than SLTs (Chau *et al*, 1998). A
3 retrospective, single centre study comparing SLT and ROTEM in post-operative bleeding in
4 adult liver transplant (LT) patients found several ROTEM parameters predicted bleeding
5 (cut-offs shown in brackets): EXTEM CT (≥ 65 secs), INTEM CFT (≥ 181 secs), FIBTEM A10 (≤ 13
6 mm) and FIBTEM MCF (≤ 15 mm) (area under the curve (AUC) 0.682, 0.615, 0.615 & 0.611
7 respectively) compared to no SLT tests (Dotsch *et al*, 2017). In cirrhotic patients, ROTEM
8 values were associated with bleeding, specifically, reduced EXTEM MCF (median values
9 bleeding vs non-bleeding: 38 mm vs 43 mm) and FIBTEM MCF (8mm vs 13 mm), and these
10 values were associated with lower factor XIII levels (Bedrelli *et al*, 2016).

11

12 A prospective observational study in 263 LT patients with transfusion thresholds based on
13 SLTs, found the best threshold that predicted platelet transfusion was A10 (EXTEM) ≤ 35
14 mm, and for fibrinogen an A10 (FIBTEM) ≤ 8 mm (Blasi *et al*, 2012), with a negative
15 predictive value (NPV) 95% and positive predictive value (PPV) 27%. A retrospective analysis
16 of ROTEM datasets in 239 LT patients concluded that the EXTEM and FIBTEM A5 measures
17 can be used to guide therapy (Song *et al* 2014) with an EXTEM A5 < 27 mm predicting
18 platelet count $< 50 \times 10^9$ per litre and FIBTEM A5 < 5 mm predicting fibrinogen < 1.0 g/l.
19 Patients with values above these ranges were unlikely to bleed.

20

21 **Diagnosis of bleeding/coagulopathy**

22 SLTs frequently indicate a hypocoagulable state in patients with liver disease, whereas VHAs
23 exhibit a spectrum from hypo- to hypercoagulable. In a cohort of 273 patients with cirrhosis,
24 TEG parameters were within normal limits, although the MA decreased in proportion to the

1 severity of liver disease and degree of thrombocytopenia (Stravitz *et al*, 2012). A good
2 correlation has been reported between the MCF and platelet count and fibrinogen levels
3 (Roullet *et al*, 2010). But, although TEG ff and FIBTEM correlate well with Clauss fibrinogen,
4 they can overestimate low levels (<1.0 g/l) especially at the time of graft reperfusion, and
5 should be interpreted with caution (Yang *et al*, 2014).

6

7 Hyperfibrinolysis is a significant cause of non-surgical bleeding in LT, with the highest
8 incidence occurring immediately after graft reperfusion. A prospective observational study
9 in 37 LT comparing ROTEM and TEG (Abuelkasem *et al*, 2016) showed that tissue factor-
10 triggered ROTEM tests were more sensitive than contact-activated kaolin TEG in identifying
11 hyperfibrinolysis. (This study is limited by using VHA manufacturers' definitions for lysis,
12 without an additional gold standard measure (ML>15% ROTEM; Lysis30>8% TEG)). A
13 heparin-like effect (HLE) due to release of endogenous heparinoids at the time of graft
14 reperfusion is commonly seen on VHA (Pivalizza *et al*, 1998) but whether this transient
15 effect contributes to bleeding is controversial. It is recommended that TEG heparinase
16 assays or HEPTTEM are run immediately after graft reperfusion (Agarwal *et al*, 2008).

17

18 **Use of ROTEM/TEG for guiding transfusion and haemostatic therapy**

19 The perceived utility of TEG and ROTEM for intra-operative haemostatic monitoring has led
20 to VHAs becoming a standard of care in many LT units, despite the lack of high quality data.
21 The European Society of Anaesthesiologists guidelines recommend VHA use during LT
22 (grade1C) (Kozek-Langenecker *et al*, 2017). From a practical stance, the major benefit is for
23 patients with a high risk of bleeding (Model for End Stage Liver Disease score (MELD) >21
24 and /or expected difficult surgical dissection) and those poly-transfused intra-operatively. In

1 this setting ROTEM has been shown to significantly reduce blood component use ($p = <$
2 0.05) and to reduce post-operative complications (Alamo *et al*, 2013).

3
4 Other observational studies have shown VHA-based algorithms reduce transfusion during LT
5 (Kang *et al*, 1985; Trzebicki *et al*, 2010) and increase numbers of patients free from
6 transfusions. One study showed a rise of non-transfused patients from 5 to 24% ($p < 0.001$),
7 with concomitant reduction of massive transfusion from 13 to 2% ($p < 0.005$) (Leon-Justel *et*
8 *al*, 2015). To date, the only RCT ($n = 28$) of TEG versus SLT demonstrated a significant
9 reduction in FFP administration in the TEG group with a trend to less transfusion overall
10 (Wang *et al*, 2010). A Cochrane review (Gurusamy *et al*, 2011) concluded that VHA may
11 decrease blood loss and transfusion requirements in LT.

12
13 There are a number of treatment algorithms developed by different LT centres. The
14 consensus in the liver transplant community is not to correct VHA abnormalities unless
15 there is active bleeding. The cut off values that would trigger pre-emptive treatment have
16 not been established and may lie significantly outside normal ranges (i.e. $>15\%$) (Wang *et al*,
17 2012).

18
19 The clot strength is a composite measure of fibrinogen-platelet interaction, and VHA
20 monitoring without assessment of fibrinogen can lead to increased transfusion of platelets
21 (Larsen *et al*, 2011) with potentially detrimental effects (de Boer *et al*, 2008). Algorithms
22 that include TEG ff or FIBTEM cut offs for fibrinogen administration in patients who are
23 actively bleeding increases the use of fibrinogen replacement but significantly reduces
24 overall transfusion (De Pietri *et al*, 2016; Noval-Padillo *et al*, 2010). There is less information

1 for thresholds to guide prothrombin complex concentrate (PCC) or FFP, but a retrospective
2 review of 266 LT used a CT (EXTEM) ≥ 80 s as a threshold for PCC and a CT INTEM of ≥ 240 s
3 for FFP transfusion (Kirchner et al 2014). This study showed an increased use of RBC and
4 platelets in the patients receiving PCC, however, this group had a significantly higher MELD
5 score ($p < 0.0001$) than the group that did not receive coagulation factor concentrates.

6

7 **Recommendations:**

- 8 • **PT/INR does not reliably predict bleeding risk in patients with liver disease. Grade**
9 **1B.**
- 10 • **Heparinase tests are recommended at graft reperfusion to determine the extent of**
11 **any HLE. Grade 2B.**
- 12 • **In bleeding patients, VHA (FIBTEM, TEG ff) should be used to guide fibrinogen**
13 **replacement. Grade 1C.**
- 14 • **VHA can be used in liver transplant patients to reduce overall transfusion**
15 **requirement (a normal VHA trace has a 95% NPV for transfusion requirement).**
16 **Grade 1C.**

17

18 **Cardiac surgery**

19 The use of VHA has been studied in the setting of cardiac surgery. One publication
20 compared all three VHAs in a prospective observational study of 35 patients, using them at
21 1 hr and 24 hrs post-operatively compared with SLTs, and found TEG to be the most
22 sensitive in detecting abnormal platelet counts, prolonged aPTT and reduced fibrinogen
23 (Espinosa *et al*, 2014). Sonoclot was the least sensitive, although none of the patients had

1 markedly abnormal haemostasis and clinical outcomes were not assessed (Espinosa *et al*,
2 2014).

3

4 **Prediction and diagnosis of bleeding/coagulopathy**

5 The majority of studies looking at prediction of bleeding have been small and have used
6 variable definitions of major bleeding, which makes comparison of studies difficult.
7 Preoperative (pre-bypass) VHA testing as an isolated test has not been shown to predict
8 bleeding. Post-bypass VHA testing is moderately predictive of bleeding, however most
9 studies have shown that the values obtained are often still in the normal range, and that the
10 difference between the pre- and post-bypass tests, rather than the absolute values
11 obtained, predicts bleeding. A change in any of the VHA variables >15% is most often
12 associated with increased risk of bleeding.

13

14 **Use of ROTEM/TEG/Sonoclot for guiding transfusion and haemostatic therapy**

15 VHA-directed management has been reported to improve overall clinical outcomes after
16 cardiac surgery (Pearse *et al*, 2015 Sartorius *et al*, 2014 Trevisan *et al*, 2016, Weber *et al*,
17 2012), and result in less bleeding and lower need for re-exploration after coronary artery
18 bypass grafting (CABG) (Speiss *et al*, 1995). Duration of hospitalisation was also reduced
19 (Ichikawa *et al*, 2017). Conversely, a recent systematic review of 15 randomised trials
20 involving 8737 patients found no significant difference in mortality, reoperation or
21 postoperative recovery (Serraino & Murphy, 2017), with benefits being the reduction in
22 transfusion requirements only. However, when used in combination with other techniques,
23 such as a smaller bypass circuit (Mehaffey *et al*, 2017), or a general package of intervention
24 (Ranucci *et al*, 2017) clinical outcomes have been significantly improved.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

A TEG-guided approach can reduce use of allogeneic components by up to 58%, compared to SLTs (Westbrook *et al*, 2009). Similarly, 30-80% reduction in blood component use has been demonstrated with intraoperative ROTEM (Karkouti *et al*, 2015; Royston *et al*, 2001; Romlin *et al*, 2013, Ichikawa *et al*, 2017), and in the setting of hypothermic cardiac arrest for proximal cardiac surgery (Fassl *et al*, 2013, Girdauskas *et al*, 2010).

Ak *et al*, 2009 showed that using the TEG parameters R time and MA to guide management led to a significant reduction in platelet and FFP use (n = 110) when compared to clinician-directed transfusion without TEG (n = 114)(Ak *et al*, 2009). These results were replicated in a second study (Aoki *et al*, 2012). Systematic reviews of nine (Fahrendorff *et al*, 2017) and 15 (Serraino & Murphy, 2017) studies where patients have been randomised to VHA-directed management or empirical management, have given differing results with respect to volume of platelet transfusions. However, the new generation VHAs incorporate platelet function testing and when specific cut-off values of preoperative platelet function tests have been used to direct timing of surgery this has resulted in a significant reduction in surgical re-exploration rate, use of FFP, and use of platelet concentrates (Ranucci *et al*, 2017).

In paediatric cardiac surgery, TEG-guided management has resulted in more effective cessation of postoperative bleeding compared to SLT guided therapy (Niebler *et al*, 2012). Randomised trials have shown the same effect following ROTEM-directed therapy with significant reductions in postoperative bleeding and blood component requirements (Nakayama *et al*, 2015; Romlin *et al*, 2013). Analysis of ROC curves of ROTEM parameters in

1 150 children, showed EXTEM CT>111 s, EXTEM A10 <38 mm and FIBTEM A10 <3 mm could
2 be used to guide management (Faraoni *et al*, 2015).

3
4 Studies have also found good correlation between FIBTEM and Clauss fibrinogen in adults
5 (Mace *et al*, 2016; Ogawa *et al*, 2012) and children (Pekelharan *et al*, 2014) and decreasing
6 levels of fibrinogen can be quickly determined (Romlin *et al*, 2013). Ortmann *et al*, 2015
7 showed superiority of FIBTEM over Clauss fibrinogen. VHA can be used as a valid assessment
8 of fibrinogen concentration to guide fibrinogen replacement leading in some cases to
9 complete avoidance of FFP and platelets (Rahe-Meyer *et al*, 2009).

10

11 In general, reduction in blood component use may be equal when guided by VHA or
12 laboratory-derived algorithms but both appear to be better than clinician directed
13 transfusion (Avidan *et al*, 2014) and the delays in waiting for SLTs support the need for VHAs
14 in the management of these patients.

15

16 **Recommendations:**

- 17 • **Pre-operative VHA has not been shown to be useful for predicting bleeding in patients**
18 **having cardiac surgery. Grade 2B.**
- 19 • **Patients with a normal or abnormal postoperative VHA and no bleeding should not**
20 **receive empirical blood components. Grade 2A.**
- 21 • **Superiority over laboratory tests in predicting bleeding has not been consistently**
22 **demonstrated. Grade 2C.**
- 23 • **A single post-operative VHA test may not be useful for prediction of bleeding.**
24 **However, if deterioration of VHA parameters is seen on repeat testing, the patient**

1 should be closely monitored for bleeding and intervention with appropriate blood
2 components should be considered. Grade 2B.

3 • Cardiac surgery services should use transfusion protocols based on VHA testing to
4 reduce use of blood components and potentially improve clinical outcomes in bleeding
5 patients. Grade 2B.

6 • VHA can be used as a valid assessment of fibrinogen concentration to guide fibrinogen
7 replacement. Grade 1B.

9 Trauma

10 Prediction of bleeding and coagulopathy

11 Many observational studies have explored whether VHA can reliably predict bleeding.
12 Sixteen studies gave a threshold VHA parameter that could be used as a cut-off
13 above/below which transfusion was more likely to be given, but very few gave data on the
14 sensitivity/specificity of their reported VHA threshold. Broadly, the majority of the
15 thresholds that predicted transfusion represented measurements of clot strength. Only one
16 of these thresholds (EXTEM A5 35 mm, below which a patient is deemed to be at high risk of
17 bleeding) has been externally validated (Davenport *et al*, 2011a - validated by Hagemo *et al*,
18 2015), limiting the validity of the other results to centres outside the reporting institution.
19 Davenport demonstrated that EXTEM A5 of 35 mm or more had a high NPV for transfusion
20 need. The finding of VHA-detected fibrinolysis, commonly reported with TEG as >3% lysis,
21 has also consistently been associated with patients who have required large transfusion
22 volumes, however VHA are insensitive to mild/moderate fibrinolysis and should not be used
23 to withhold TXA (Raza *et al*, 2013). Several systematic reviews have highlighted the limited

1 nature of the available evidence (Da Luz *et al*, 2014; Whiting *et al*, 2015; Hass *et al*, 2014,
2 Hunt *et al*, 2014).

3

4 **Diagnosis of traumatic coagulopathy/bleeding**

5 VHA tests have been used in a variety of ways to diagnose traumatic coagulopathy. A
6 common method has been to explore the relationship between VHA and SLTs. Many studies
7 report good correlations, with the majority defining coagulopathy using a PT-based
8 measure. More trauma patients are found to have clotting abnormalities using ROTEM than
9 using SLTs (64% vs. 10.5%)(Doran *et al*, 2010). No comparative data are available for TEG.

10

11 VHA measures which are used to diagnose trauma coagulopathy vary but can be broadly
12 summarised by three main changes: prolongation of clot formation; reduction in clot
13 strength and increase in fibrinolysis. The most common abnormalities include: reduction in
14 A and MCF (ROTEM) (Wooley *et al*, 2013, Meyer *et al*, 2014, Tauber *et al*, 2011) and
15 reduction in MA (TEG) (Meyer *et al*, 2014, White *et al*, 2015) – all measures of clot strength,
16 and low clot strength is viewed as an important marker suggesting higher bleeding risk.
17 However, no consensus value is yet agreed – for example Davenport *et al*, 2011 used an
18 EXTEM A5 of ≤ 35 mm as diagnostic of trauma coagulopathy whereas Hagemo *et al*, 2015
19 used ≤ 40 mm. Other reported VHA changes include prolongation of CT and CFT and
20 reduction of alpha angle (ROTEM) (Tauber *et al*, 2011), prolonged R times (TEG) (Meyer *et*
21 *al*, 2014) and increased LY30 (rTEG) (Moore *et al*, 2017).

22

23 **VHA for guiding transfusion and haemostatic therapy**

1 VHA guided transfusion algorithms for management of severe trauma bleeding have been
2 widely reported using TEG and ROTEM. TEG algorithms vary according to institution,
3 although the general principles were similar across all studies. There were far fewer ROTEM
4 data available and most studies arise from the same institution (Innerhofer *et al*, 2017,
5 Schochl *et al*, 2010 and 2011). These studies provide ROTEM values for transfusion of
6 fibrinogen concentrate and PCC, with no clear guide for platelet transfusion and no mention
7 of fibrinolysis.

8

9 The observational studies provide low quality data suggesting that VHA-guided transfusion
10 algorithms (mostly TEG) reduce mortality (Johansson *et al*, 2009; Kashuk *et al*, 2012; Schochl
11 *et al*, 2010; Tapia *et al*, 2013); change transfusion practices when compared to empiric
12 therapy (Mamczak *et al*, 2016, Tapia *et al*, 2013) and reduce/avoid allogeneic transfusion
13 (Schochl *et al*, 2011a, Yin *et al*, 2014). Data from a pre- and post-implementation military
14 study demonstrated increased use of blood components (platelets four fold and
15 cryoprecipitate two fold) after incorporating ROTEM into resuscitation practices (Prat *et al*,
16 2017) despite similar patient characteristics and rates of coagulopathy. This study suggests
17 that non VHA-based transfusion may underestimate the need for platelets and fibrinogen
18 supplementation.

19

20 One RCT using rapid-TEG (Gonzalez *et al*, 2016) reported a significant reduction in death at
21 28 d with VHA: 20 deaths SLT (36.4%) vs. 11 VHA (19.6%). Median times to death were
22 shorter in the VHA arm (4.2 h vs. 10.4 h) and numbers of haemorrhagic deaths lower (8.9%
23 vs. 20%). This study provides evidence that VHA-guided transfusion may be beneficial for
24 the management of acute bleeding in trauma, over and above the effects of empiric 1:1:1

1 transfusion. However, the study's limitations must be highlighted: it was single centre; large
2 volumes of crystalloids were used in resuscitation; participants were allocated to study arms
3 according to the week of the year, and after two-thirds of the participants were enrolled the
4 VHA algorithm was changed. It is impossible to say what effect this would have on outcome
5 but raises questions about the overall validity of the study.

6

7 A second single-centre RCT used ROTEM guided thresholds to compare FFP with factor
8 concentrates (fibrinogen concentrate (FgC) and PCC) (Innerhofer *et al*, 2017). The trial used
9 dual ROTEM measures (FIBTEM A10 >8 mm, EXTEM CT <78 s) in combination with a clinical
10 measure of bleeding to define achievement of haemostasis with the primary endpoint of
11 multiple organ failure. As a result of high treatment failure in the FFP arm (inability to
12 correct coagulopathy and need for rescue therapy with PCC) the study was terminated
13 early. The authors reported an association between clinically relevant bleeding and ROTEM
14 measurements that could be used as a threshold to withhold transfusion. A large multi-
15 centre RCT (iTACTIC) evaluating VHA- and SLT-based transfusion algorithms in trauma
16 haemorrhage is due to be completed in 2018 and results are awaited (NCT02593877).

17

18 **Recommendations:**

- 19 • **Normal VHA results confer a high negative predictive value for transfusion need,**
20 **enabling the clinical team to monitor the patient closely without immediate**
21 **activation of the major haemorrhage protocol. Grade 2B.**
- 22 • **Low clot strength measures on TEG and ROTEM and lysis of greater than 3% on TEG**
23 **may be used as an indicator that a trauma patient is at higher risk of requiring RBC**
24 **and blood components. Grade 2C.**

1 • **VHA, particularly TEG, may reduce mortality and reduce transfusion exposure and**
2 **if available may be considered for transfusion guidance in trauma haemorrhage.**

3 **Grade 2B.**

4 • **Tranexamic acid should not be withheld based on the TEG or ROTEM parameters.**

5 **Grade 1B.**

6

7 **Practical use of VHA devices.**

8 The published literature focuses on the use of VHAs to enable early identification of
9 coagulopathy and to guide transfusion of blood components. From a practical point of view
10 it is important to repeat VHA tests after transfusion to assess the effect of haemostatic
11 treatment interventions and to determine that there is no further deterioration in the
12 haemostatic profile in the context of ongoing bleeding. However, in the clinical setting, the
13 confirmation of normal coagulation is one of the most valuable aspects of VHAs. Not only
14 does this reduce unnecessary transfusion of blood components but it also directs clinical
15 management to address the underlying cause of haemorrhage. This effect is not possible to
16 quantify but is reinforced by clinicians practicing in units with access to VHAs.

17

18 **General practice points for managing major haemorrhage using VHA:**

19 • **Transfusion algorithms should be adapted according to local normal ranges and**
20 **locally validated.**

21 • **Normal VHA parameters are a useful indicator that bleeding due to coagulopathy is**
22 **unlikely and transfusion of blood components is unlikely to be needed.**

- 1 • **An abnormal VHA result is relatively poor at predicting patients who will bleed and**
2 **changes in serial measurements may be more valuable.**
- 3 • **When blood component transfusion is necessary, the use of VHA to guide and**
4 **monitor replacement has generally been found to reduce the volumes required**
5 **and improve other measures of outcome.**

6

7 **How to approach a VHA trace – general principles for guiding transfusion therapy**

8 There are no universally agreed algorithms however the general principles of how to
9 approach VHA-guided transfusion are set out in Table 2.

10

11 **Areas for future research**

12 The following areas for future research are suggested:

- 13 • Define measures for achievement of haemostasis to provide a consensus outcome
14 for clinical study reporting, so that VHA results can be compared across studies and
15 across patient groups
- 16 • Clinical studies to compare the efficacy and cost effectiveness of VHA-supported
17 transfusion algorithms with standard care during obstetric and trauma bleeding
- 18 • Large multi-centre clinical trials evaluating TEG or ROTEM algorithms in major
19 haemorrhage using standardised intervention points as well as standardised
20 interventions, allowing comparison between studies
- 21 • Future studies are required to establish if improvement in the VHA profile equates to
22 improvement in clinical outcome.

23 **Conclusion**

1 VHA devices have practical advantages as point of care devices for monitoring major
2 haemorrhage including speed of results and a set of parameters that assesses a global
3 coagulation profile. However, the lack of a systematic approach to their use, with low
4 quality published data that has not been clearly linked to important clinical outcomes means
5 that, at present, the evidence base to guide practice is limited.

1 **Acknowledgements**

2 The authors wish to thank Carolyn Doree and the NHS Blood and Transplant Systematic
3 Review Initiative for help in undertaking the literature search.

4 The BSH Haemostasis and Thrombosis task force member was Professor Mike Laffan. The
5 authors would like to thank him, the BSH sounding board, and the BSH guidelines
6 committee for their support in preparing this guideline.

7 All authors reviewed the literature search and contributed to the drafting and editing of the
8 manuscript.

9

10 **Declaration of Interests**

11 The BSH paid the expenses incurred during the writing of this guidance.

12 All authors have made a declaration of interests to the BSH and Task Force Chairs which may
13 be viewed on request. The following authors have the following declarations of interest: PC:
14 research support from CSL Behring, Werfen and Haemonetics, paid consultancy from
15 Werfen and CSL Behring, speaker fees from CSL Behring, educational grant from CSL
16 Behring; SM: Haemonetics Scientific Advisory Council 2017; AK: AK's institution has
17 received educational grant funding from Haemonetics and Hemosonics LLC for conducting
18 studies using VHA; RD: paid consultancy for LFB, RD's institution has received reagent and
19 equipment support from TEM; NC: paid consultancy for LFB, NC's institution has received
20 reagent and equipment support from TEM. ML has received financial reimbursement
21 (consultancy fees and speaker fees) from LFB, CSL, Behring, Pfizer and Shire

22 The following members of the writing group: SP, DK, HM, have no conflicts of interest to
23 declare.

24

1 **Review Process**

2 The document will be reviewed regularly by the relevant Task Force and the literature
3 search will be re-run every three years to search for any RCT or other high quality data that
4 is either new or that may have been missed. The document will be archived and removed
5 from the BSH current guidelines website if it becomes obsolete. If new recommendations
6 are made an addendum will be published on the BSH guidelines website ([www.bsh-](http://www.bsh.org.uk)
7 [h.org.uk](http://www.bsh.org.uk)).

8

9 **Disclaimer**

10 While the advice and information in this guidance is believed to be true and accurate at the
11 time of going to press, neither the authors, the BSH nor the publishers accept any legal
12 responsibility for the content of this guidance.

13

14 **Supporting Information**

15 Additional supporting information may be found in the online version of this article:


16 **Appendix S1:** Search narrative; methodology for inclusion of studies in this guideline and
17 the PRISMA flow diagram of included studies.

18


1 **Figure 1.**

2
3
4
5

a) Thromboelastography




b) Thromboelastometry



6
7
8
9

c) Sonoclot



10
11
12
13
14
15
16
17
18
19
20
21
22

Whole blood is placed in to the cup for each device. Activators are added, as required, and as the test is started a pin is placed in to the middle of the blood. The cup or the pin moves relative to the other part of the machine and as the clot forms the resistance to movement that is built up by fibrin strands coupling the pin and cup together is translated by a variety of methods into a graphical trace. A) TEG: the cup moves through a predefined arc ($4^{\circ}45'$) and resistance to movement is detected by an electromechanical transducer on the pin (Figure provided courtesy of Haemonetics). B) ROTEM: differs from TEG in that the pin oscillates through a known arc ($4^{\circ}75'$) and detection of resistance to movement is picked up by changes to light transmission which is then converted into a TEM trace (TEMogram) (Figure provided courtesy of Instrumentation Laboratory). C) Sonoclot: The plastic pin, which is mounted on to an ultrasonic transducer, vibrates vertically by 1 micrometre distances at 200Hz and resistance is detected by an electromechanical transducer.

1 **Table 1a. TEG reagents**

	TEG 5000 (cup & pin method)	TEG 6s (cartridge method)	What the trace looks at:
Sample type	Fresh WB Citrated WB	Citrated WB	-
Tests available	<i>'Plain cup'</i> : Kaolin	<i>CK</i> : Kaolin, Ca	Standard clot formation – activating the intrinsic pathway
	<i>'Heparinase cup'</i> : Kaolin, heparinase	<i>CKH</i> : Kaolin, heparinase, Ca	When compared to a standard kaolin activated trace a shorter R time suggests the presence of heparin
	<i>rTEG</i> : Kaolin, TF	<i>CRT</i> : Kaolin, TF, Ca	Standard clot formation activating both intrinsic and extrinsic pathways (particularly helpful for major haemorrhage and rapid results)
	<i>FF</i> : TF, Reopro	<i>CFF</i> : TF, Reopro, Ca	Platelet inhibitor added: contribution of fibrinogen to clot remains. When trace is compared to a standard kaolin trace the platelet contribution can be estimated

2 The words in italics indicate the names given to the assays by the manufacturer. The reagents used in these
3 assays are described beneath each italicised name.

4 Key: Ca – calcium chloride; FF – functional fibrinogen; Reopro – a GPIIb/IIIa inhibitor, inhibiting platelet
5 activity; rTEG – rapid TEG; R time = reaction time; TF – tissue factor; WB – whole blood

6
7 **Table 1b. ROTEM reagents**

	Gamma and delta (cup and pin method)	Sigma (cartridge method)	What the trace looks at:
Sample type	Citrated WB	Citrated WB	-
Tests available	<i>INTEM</i> : Ellagic acid	<i>'ROTEM sigma complete cartridge'</i> : Includes: FIBTEM, EXTEM, INTEM and APTEM channels	INTEM: Standard clot formation – activating the intrinsic pathway
	<i>EXTEM</i> : TF	<i>'ROTEM sigma complete +hep cartridge'</i> : Includes: FIBTEM, EXTEM, INTEM and HEPTTEM channels	EXTEM: Standard clot formation – activating the extrinsic pathway
	<i>HEPTTEM</i> : Ellagic acid, heparinase		HEPTTEM: When compared to an INTEM trace a shorter CT time suggests presence of heparin
	<i>FIBTEM</i> : TF + cytochalasin C		FIBTEM: Platelet inhibitor added: contribution of fibrinogen to clot remains. Can compare results to EXTEM trace to get idea of platelet contribution
	<i>APTEM</i> : TF + aprotinin		APTEM: Aprotinin added: trace compared to EXTEM, differences in MA/MCF suggest contribution of fibrinolysis

8 The words in italics indicate the names given to the assays by the manufacturer. The reagents used in these
9 assays are described beneath each italicised name.

1 Key: CT – clotting time; MA – maximum amplitude; MCF – maximal clot formation; TF – tissue factor; WB –
2 whole blood

3

4

5 **Table 1c. Sonoclot reagents**

	Sonoclot	What the trace looks at:
Sample type	Fresh WB, Citrated WB, plasma	
Tests available	<i>kACT:</i> Kaolin	Used to manage heparin therapy (with/without aprotinin)
	<i>Son ACT:</i> Celite	Used to manage heparin therapy (without aprotinin)
	<i>aiACT:</i> Celite, clay	Used to manage heparin therapy, with aprotinin
	<i>gbACT+:</i> Glass beads	Standard clotting assessment and platelet function for use in non-heparinised patients
	<i>H-gbACT+:</i> Glass beads + heparinase	Standard clotting assessment and platelet function for use in heparinised patients


6 The words in italics indicate the names given to the assays by the manufacturer. The reagents used in these
7 assays are described beneath each italicised name.

8 Key: WB – whole blood

9


10

1 **Figure 2.**
 2
 3 **TEG and ROTEM traces.**



4
 5
 6 TEG and ROTEM traces can be broadly divided into 4 main sections: (a) time to first fibrin formation (reaction[®]
 7 time - TEG5000; activated clotting time (ACT) – TEG6s; clotting time (CT) – ROTEM); (b) kinetics of fibrin
 8 polymerisation which has two parameters which are directly interchangeable (alpha angle used by both
 9 devices) and additionally the time it takes from first fibrin formation to when arbitrarily the clot is 20mm wide
 10 (kinetics (K)time – TEG5000; clot formation time (CFT) – ROTEM); (c) measures of clot strength – often
 11 demarcated at 5 minute intervals (amplitude (A) - A30 – TEG clot strength at 30 minutes; clot amplitude (CA) -
 12 CA30 – ROTEM clot strength at 30 minutes) and with a peak measurement (maximal amplitude (MA) – TEG;
 13 maximum clot formation (MCF) – ROTEM); (d) measures of clot breakdown/lysis, usually presented as a
 14 percentage of reduction in the clot strength measure compared to maximal measurement (Lysis (Ly) – TEG;
 15 clot lysis/lysis index/maximal lysis (CL/LI /ML)– ROTEM).
 16
 17


- 1 **Figure 3.**
- 2 **Sonoclot trace.**
- 3



- 4
- 5
- 6
- 7 The Sonoclot trace is shown above and is divided into 4 distinct sections: (a) Activated clotting time (ACT) – the
- 8 time in seconds from the start of the test until first fibrin is formed; (b) Clot rate – the maximum slope during
- 9 initial clot formation as shown by the line R1 above; (c) time to peak – the time in seconds which provides an
- 10 indication of how rapidly fibrinogen is converted to fibrin and how well platelets are activated; (d) Clot
- 11 retraction – this shows whether platelets are working normally by retracting after activation.
- 12

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27


Figure 4.
TEG6s technology.



The TEG6s measures resonance frequency. The blood sample is exposed to various frequency vibrations and the up down motion of the surface of the blood meniscus is measured by LED illumination. As the clot forms the resonance alters in a reproducible way and can be converted into the TEGogram. (Figure provided courtesy of Haemonetics).

1 **Table 2.**

2



3

4

	CLOT INITIATION	CLOT STRENGTH		CLOT LYSIS
Test result shows:	Prolonged R, ACT or CT	Reduced MA/MCF, normal fibrinogen†	Reduced MA/MCF, low fibrinogen†	LY-30 >8% Li30 >15%
What does this mean?	Low clotting factors and/or low fibrinogen level Warfarin use Heparin use DOAC use (not Apixaban)	Low platelets	Low fibrinogen	VHA detected fibrinolysis*
Therapy recommended	FFP (PCC might be considered)	Platelets	Cryoprecipitate or fibrinogen concentrate	Consider additional anti-fibrinolytic*
Therapy groups				
Obstetric	FFP if R or CT above the normal range. PCC is not recommended	No data are available to guide platelet transfusion	Cryoprecipitate or fibrinogen concentrate if FIBTEM <7 mm or <12 mm in severe bleeding	No data are available for guiding antifibrinolytic therapy
Liver	FFP if results above normal range (PCC might be considered)	EXTEM MCF < 35 mm	FIBTEM < 7 mm	Fibrinolysis at reperfusion may correct spontaneously. Anti-fibrinolytics are indicated in most other circumstances.
Cardiac	FFP if > 15% above ULN	Platelets	Cryoprecipitate or FgC	
Trauma	FFP if results at upper end or above normal range	Give platelets if MA/MCF at lower end or below the	Cryoprecipitate or FgC if FIBTEM or ff at lower end or	TEG LY-30 ≥3% indicates clinically important lysis

	PCC not recommended	normal range whilst ff or FIBTEM normal	below the normal range	
--	---------------------	--	---------------------------	--

1 † Clot strength measures are highly dependent on platelets and fibrinogen. To differentiate low clot strength due to loss of
2 platelet function or from that due to low fibrinogen levels, the clot strength of the fibrinogen assay (ff – TEG; FIBTEM –
3 ROTEM) should be compared with the standard TEG or ROTEM EXTEM trace, respectively. A low overall clot strength with a
4 normal ff/FIBTEM would suggest lack of platelets contributing to the clot, whereas a low overall clot strength with a
5 concomitant low ff/FIBTEM would point to lack of fibrinogen
6 *Do not withhold an anti-fibrinolytic if is it clinically indicated and within 3 hours of injury or start of postpartum
7 haemorrhage
8
9 Key: ACT – activated clotting time; CT – clotting time; ff – functional fibrinogen; FFP – fresh frozen plasma; FgC – fibrinogen
10 concentrate; Li30 – lysis at 30 minutes; LY-30 – lysis at 30 minutes; MA – maximal amplitude; MCF – maximum clot
11 firmness; PCC – prothrombin complex concentrate; R – reaction time; ULN – upper limit of normal; VHA – viscoelastic
12 haemostatic assay
13
14
15